- Home
- ATTO vs SVRA Comparison
ATTO vs SVRA Comparison
Compare ATTO & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATTO | SVRA |
|---|---|---|
| Founded | 2023 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2026 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ATTO | SVRA |
|---|---|---|
| Price | $14.12 | $4.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $42.20 | $11.06 |
| AVG Volume (30 Days) | 416.7K | ★ 2.4M |
| Earning Date | 09-02-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,406.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.94 | $3.86 |
| 52 Week High | $28.00 | $7.01 |
Technical Indicators
Market Signals| Indicator | ATTO | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 31.42 | 40.17 |
| Support Level | N/A | N/A |
| Resistance Level | $18.38 | $5.53 |
| Average True Range (ATR) | 1.18 | 0.22 |
| MACD | -0.23 | -0.02 |
| Stochastic Oscillator | 21.53 | 28.74 |
Price Performance
Historical ComparisonAbout ATTO Attovia Therapeutics Inc. Common Stock
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).